Penn Medicine Health System, University of Pennsylvania
Philadelphia, Pennsylvania
Dr. Simpkins, MD is an Associate Professor in the Division of Gynecology Oncology and Department of OB-GYN at the University of Pennsylvania (UPENN). She is Director of Clinical and Translational Gynecologic Oncology Research for Penn Medicine Health System and Co-Principal Investigator (PI) for The Center of Excellence for Ovarian Cancer (TCE) at the Abramson Cancer Center at UPENN. She also is a member of the Phase I/Developmental Therapeutics Committee for gynecological cancers for the NRG Cooperative Group. Dr. Simpkins completed her OB-GYN residency at Johns Hopkins University and Gynecology Oncology fellowship at the Cleveland Clinic Foundation. She completed a Cancer Research Training fellowship focusing on ovarian cancer signal transduction at the National Cancer Institute and a post-doctoral fellowship investigating anti-estrogen resistance in ovarian cancer. She is a translational scientist and the overarching goal of her laboratory is to identify novel strategies to overcome drug resistance, such as PARP inhibitor and platinum resistance, in ovarian cancer and bring these new findings to the clinic. Her laboratory has developed a preclinical drug development platform which is comprised of primary tumor cultures, organoids and >100 patient-derived xenografts from ovarian and uterine tumors which have been characterized by genomics and proteomics. She is using this platform to identify biomarkers predicting response to DNA damage response inhibitors and optimize strategies to overcome resistance. Ultimately, Dr. Simpkins’ goal is to bring therapies with strong preclinical evidence learned in her laboratory to the clinic via biomarker focused phase I/II clinical trials.
AstraZeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Grant/Research Support; Instill Bio (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support; Repare Therapeutics (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Grant/Research Support
Friday, April 29, 2022
11:20 AM – 1:25 PM
Friday, April 29, 2022
12:05 PM – 12:25 PM
Friday, April 29, 2022
1:05 PM – 1:25 PM